Pediadermics Eczema 3

Colloidal Oatmeal, Dimethicone


Renu Laboratories, Inc.
Human Otc Drug
NDC 76348-580
Pediadermics Eczema 3 also known as Colloidal Oatmeal, Dimethicone is a human otc drug labeled by 'Renu Laboratories, Inc.'. National Drug Code (NDC) number for Pediadermics Eczema 3 is 76348-580. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Pediadermics Eczema 3 drug includes Dimethicone - 3.36 g/168g Oatmeal - .168 g/168g . The currest status of Pediadermics Eczema 3 drug is Active.

Drug Information:

Drug NDC: 76348-580
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Pediadermics Eczema 3
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Colloidal Oatmeal, Dimethicone
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Renu Laboratories, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:DIMETHICONE - 3.36 g/168g
OATMEAL - .168 g/168g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Oct, 2020
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 10 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part347
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Renu Laboratories, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000010282
N0000185371
N0000185375
N0000175629
N0000184306
M0000728
M0006342
M0016962
N0000185016
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:92RU3N3Y1O
8PI54V663Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Skin Barrier Activity [PE]
Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Dietary Proteins [CS]
Plant Proteins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Dietary Proteins [CS]
Grain Proteins [EXT]
Increased Histamine Release [PE]
Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Plant Proteins [CS]
Skin Barrier Activity [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
76348-580-06168 g in 1 TUBE (76348-580-06)01 Oct, 2020N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose skin protectant skin protectant

Product Elements:

Pediadermics eczema 3 colloidal oatmeal, dimethicone cetostearyl alcohol meadowfoam seed oil xanthan gum carbomer homopolymer, unspecified type helianthus annuus seed wax ceramide 1 jojoba oil dimethicone dimethicone rice bran glyceryl monostearate sodium stearoyl lactylate oatmeal oatmeal glycerin cetyl alcohol ascorbyl palmitate candelilla wax propanediol niacinamide stearic acid water phytosphingosine palmitic acid biosaccharide gum-1 sodium lauroyl lactylate cholesterol ceramide np polyglycerin-3 caprylyl glycol saccharide isomerate caprylhydroxamic acid ceramide ap edetate disodium hexanediol sodium hydroxide hyaluronate sodium oat maltodextrin tocopherol sodium pyrrolidone carboxylate ophiopogon japonicus root

Indications and Usage:

Uses temporarily protects sensitive skin and helps relieve minor skin irritation due to eczema. temporarily helps prevent and relieve chapped or cracked skin.

Warnings:

Warnings for external use only

When Using:

When using this product do not get into eyes do not apply before bathing or showering

Dosage and Administration:

Directions for best results, follow the rule of "3" apply liberally to skin at least "3" times a day apply within "3" minutes of bathing keep a "3" location supply (home, on-the-go and school) !

Stop Use:

Stop use and ask a doctor if condition worsens symptoms last more than 2 weeks or clear up and occur again within a few days.

Package Label Principal Display Panel:

Eczema 3 tube artwork eczema 3 tube art

Further Questions:

Questions? pediadermics@gmail.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.